Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Neuronal impact of patient-specific aberrant NRXN1α splicing [whole]

ABSTRACT: We performed targeted long-read and short-read RNA sequencing to identify and quantify NRXN1 isoforms in human post-mortem dlPFC and hiPSC-neurons derived from controls and NRXN1+/- individuals. We also performed whole transcriptome RNA seuqencing and 10x genomics single cell sequencing to determine transcriptional changes in NRXN1+/- hiPSC-neurons compared to controls.

ORGANISM(S): Homo sapiens

PROVIDER: GSE137101 | GEO | 2019/09/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Neuronal impact of patient-specific aberrant NRXN1α splicing [targeted]

Project description:We performed targeted long-read and short-read RNA sequencing to identify and quantify NRXN1 isoforms in human post-mortem dlPFC and hiPSC-neurons derived from controls and NRXN1+/- individuals.

2019-09-10 | GSE137127 | GEO

Schizophrenia: postmortem dorsal lateral prefrontal cortex (DLPFC)

Project description:RNA-Seq analysis of post-mortem tissue from DLPFC of 19 schizophrenia patients and 19 controls.

2016-12-30 | GSE87194 | GEO

Gene Network Dysregulation in Dorsolateral Prefrontal Cortex Neurons of Humans with Cocaine Use Disorder

Project description:total RNA-sequencing on dlPFC neurons from 19 human cocaine addicts (1-19) and 17 healthy controls (21-40)

2018-01-01 | GSE99349 | GEO

Cross-Platform Validation of Neurotransmitter Release Impairments in Schizophrenia Patient-Derived NRXN1-Mutant Neurons

Project description:Heterozygous NRXN1 deletions constitute the most prevalent currently known single-gene mutation associated with schizophrenia, and predispose to multiple other neurodevelopmental disorders. Previous studies showed that engineered heterozygous NRXN1 deletions impaired neurotransmitter release in human neurons, suggesting a synaptic pathophysiological mechanism. Utilizing this observation for drug discovery, however, requires confidence in its robustness and validity. Here, we describe a multi-center effort to test the generality of this pivotal observation, using independent analyses at two laboratories of patient-derived and newly engineered human neurons with heterozygous NRXN1 deletions. We show that in neurons that were trans-differentiated from induced pluripotent stem cells derived from three NRXN1-deletion patients, the same impairment in neurotransmitter release was observed as in engineered NRXN1-deficient neurons. This impairment manifested as a decrease in spontaneous synaptic events and in evoked synaptic responses, and an alteration in synaptic paired-pulse depression. Nrxn1-deficient mouse neurons generated from embryonic stem cells by the same method as human neurons did not exhibit impaired neurotransmitter release, suggesting a human-specific phenotype. NRXN1 deletions produced a reproducible increase in the levels of CASK, an intracellular NRXN1-binding protein, and were associated with characteristic gene expression changes. Thus, heterozygous NRXN1 deletions robustly impair synaptic function in human neurons regardless of genetic background, enabling future drug discovery efforts.

2021-03-12 | GSE168762 | GEO

Transcriptional signatures of schizophrenia in hiPSC-derived NPCs and neurons are concordant with signatures from post mortem adult brains

Project description:Whereas highly penetrant variants have proven well-suited to human induced pluripotent stem cell (hiPSC)-based models, the power of hiPSC-based studies to resolve the much smaller effects of common variants within the size of cohorts that can be realistically assembled remains uncertain. In developing a large case/control schizophrenia (SZ) hiPSC-derived cohort of neural progenitor cells and neurons, we identified and accounted for a variety of technical and biological sources of variation. Reducing the stochastic effects of the differentiation process by correcting for cell type composition boosted the SZ signal in hiPSC-based models and increased the concordance with post mortem datasets. Because this concordance was strongest in hiPSC-neurons, it suggests that this cell type may better model genetic risk for SZ. We predict a growing convergence between hiPSC and post mortem studies as both approaches expand to larger cohort sizes. For studies of complex genetic disorders, to maximize the power of hiPSC cohorts currently feasible, in most cases and whenever possible, we recommend expanding the number of individuals even at the expense of the number of replicate hiPSC clones.

2018-02-23 | GSE106589 | GEO

Modelling schizophrenia using human induced pluripotent stem cells

Project description:Schizophrenia (SCZD) is a debilitating neurological disorder with a world-wide prevalence of 1%; there is a strong genetic component, with an estimated heritability of 80–85%1. Although post-mortem studies have revealed reduced brain volume, cell size, spine density and abnormal neural distribution in the prefrontal cortex and hippocampus of SCZD brain tissue2 and neuropharmacological studies have implicated dopaminergic, glutamatergic and GABAergic activity in SCZD3, the cell types affected in SCZD and the molecular mechanisms underlying the disease state remain unclear. To elucidate the cellular and molecular defects of SCZD, we directly reprogrammed fibroblasts from SCZD patients into human induced pluripotent stem cells (hiPSCs) and subsequently differentiated these disorder-specific hiPSCs into neurons (Supplementary Fig. 1). SCZD hiPSC neurons showed diminished neuronal connectivity in conjunction with decreased neurite number, PSD95-protein levels and glutamate receptor expression. Gene expression profiles of SCZD hiPSC neurons identified altered expression of many components of the cyclic AMP and WNT signalling pathways. Key cellular and molecular elements of the SCZD phenotype were ameliorated following treatment of SCZD hiPSC neurons with the antipsychotic loxapine. To date, hiPSC neuronal pathology has only been demonstrated in diseases characterized by both the loss of function of a single gene product and rapid disease progression in early childhood. We now report hiPSC neuronal phenotypes and gene expression changes associated with SCZD, a complex genetic psychiatric disorder. 4 samples/no replicates/genotyped for copy number variation, using the same refrence sample on nimblegen's 080131_HG18_WG_CGH_v2DCR_HX1 design, a dual color microarry, 2.1 million probes platform.

2011-08-12 | E-GEOD-30737 | biostudies-arrayexpress

Aberrant expression of lncRNAs in autistic brain

2012-09-10 | GSE36315 | GEO

Unambiguous detection of SARS-CoV-2 subgenomic mRNAs with single cell RNA sequencing

Project description:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the ongoing pandemic of coronavirus disease 2019 (COVID-19). Single cell RNA sequencing (scRNAseq) studies have been valuable for studying SARS-CoV-2 pathogenesis, but the performance of these methods to detect and quantify viral RNAs has not been evaluated. Here we develop an analysis pipeline, single cell coronavirus sequencing (scCoVseq), to quantify unambiguous reads derived from coronavirus genomic (gRNA) and subgenomic mRNAs (sgmRNAs). We use this method to compare the ability of scRNAseq methods developed by 10X Genomics to detect and quantify SARS-CoV-2 RNAs, with particular focus on sgmRNAs. We find that while sequencing libraries from 10X Genomics Chromium Next Gem Single Cell V(D)J (10X 5') contain more unambiguous reads derived from sgmRNAs due to the presence of reads spanning junctions between the viral 5' leader and sgmRNA open reading frames. We demonstrate that by extending read 1 (R1) of 10X 5' leaders we can further increase the number of unambiguous reads from SARS-CoV-2 sgmRNA resulting in more UMIs per sgmRNA per cell. Using this method, which we call 10X 5' Extended R1, we are able quantify viral sgmRNA production per cell, which we believe will improve understanding regarding the dynamics of coronavirus RNA biogenesis over time and across cell types and viruses. We believe this will improve our understanding of coronavirus pathogenesis.

2023-07-30 | GSE189900 | GEO

Aberrant expression of lncRNAs in autistic brain

Project description:To assess for the potential contribution of dysregulated long non-coding RNA expression in autism pathogenesis, we profiled lncRNAs and mRNAs from post mortem brain tissue from autism patients and age/sex matched controls 4 brain tissue samples from autism patients (2 patients, 1 prefrontal cortex and cerebellum sample from each) were compared to 4 brain tissue samples from non-affected controls (2 patients, 1 prefrontal cortex and cerebellum sample from each)

2012-09-10 | E-GEOD-36315 | biostudies-arrayexpress

hiPSC-derived motor neurons: sporadic ALS patients vs. controls

Project description:Differentiated motor neurons from hiPSC derived from peripheral nerve fibroblasts of sporadic ALS patients and evaluated the gene expression profile by means microarray-linked to specific analysis tools. Two-condition experiment, ALS patients motor neurons vs. controls. Biological replicates: 3 ALS replicates, 3 control replicates.

2015-04-25 | E-GEOD-68240 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data